366 related articles for article (PubMed ID: 30551885)
1. Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients.
Rodriguez-Freixinos V; Fariñas-Madrid L; Gil-Martin M; Barretina-Ginesta P; Romeo M; Villacampa G; Pardo B; Ahmed H; Recalde S; Piulats JM; Gómez-Plaza MC; Gil-Moreno A; Sala E; Martínez-Román S; Ponce J; Meléndez C; Carballas E; Dienstmann R; Oaknin A
Gynecol Oncol; 2019 Feb; 152(2):270-277. PubMed ID: 30551885
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study.
Ang JE; Gourley C; Powell CB; High H; Shapira-Frommer R; Castonguay V; De Greve J; Atkinson T; Yap TA; Sandhu S; Banerjee S; Chen LM; Friedlander ML; Kaufman B; Oza AM; Matulonis U; Barber LJ; Kozarewa I; Fenwick K; Assiotis I; Campbell J; Chen L; de Bono JS; Gore ME; Lord CJ; Ashworth A; Kaye SB
Clin Cancer Res; 2013 Oct; 19(19):5485-93. PubMed ID: 23922302
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different?
Tan DS; Kaye SB
Am Soc Clin Oncol Educ Book; 2015; ():114-21. PubMed ID: 25993149
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of poly (ADP-ribose) polymerase inhibitors monotherapy and the impact to subsequent platinum-based chemotherapy in breast cancer susceptibility genes1/2-mutated ovarian cancer patients with secondary platinum-sensitive relapse.
Ma Y; Liu J; Li N; Bu H; Huang Y; Jin C; Wen H; Feng S; Zhang H; Yang X; Kong B; Wu L; Song K
J Ovarian Res; 2023 Oct; 16(1):209. PubMed ID: 37891662
[TBL] [Abstract][Full Text] [Related]
5. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
[TBL] [Abstract][Full Text] [Related]
6. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP
Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458
[No Abstract] [Full Text] [Related]
7. Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes.
Momtaz P; O'Connor CA; Chou JF; Capanu M; Park W; Bandlamudi C; Berger MF; Kelsen DP; Suehnholz SP; Chakravarty D; Yu KH; Varghese AM; Zervoudakis A; Li J; Ku GY; Park JS; Shcherba M; Harding JJ; Goldberg Z; Abou-Alfa GK; Salo-Mullen EE; Stadler ZK; Iacobuzio-Donahue CA; O'Reilly EM
Cancer; 2021 Dec; 127(23):4393-4402. PubMed ID: 34351646
[TBL] [Abstract][Full Text] [Related]
8. PARP inhibitors decrease response to subsequent platinum-based chemotherapy in patients with BRCA mutated ovarian cancer.
Rose PG; Yao M; Chambers LM; Mahdi H; DeBernardo R; Michener CM; AlHilli M; Ricci S; Vargas R
Anticancer Drugs; 2021 Nov; 32(10):1086-1092. PubMed ID: 34520432
[TBL] [Abstract][Full Text] [Related]
9. What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?
Liu JF; Matulonis UA
Curr Oncol Rep; 2016 May; 18(5):29. PubMed ID: 26984416
[TBL] [Abstract][Full Text] [Related]
10. BRCA1/2 testing: therapeutic implications for breast cancer management.
Tung NM; Garber JE
Br J Cancer; 2018 Jul; 119(2):141-152. PubMed ID: 29867226
[TBL] [Abstract][Full Text] [Related]
11. A real-world study of treatment patterns following disease progression in epithelial ovarian cancer patients undergoing poly-ADP-ribose polymerase inhibitor maintenance therapy.
Zhang N; Zheng H; Gao Y; Shu T; Wang H; Cai Y
J Ovarian Res; 2024 Mar; 17(1):55. PubMed ID: 38444005
[TBL] [Abstract][Full Text] [Related]
12. Diverse
Weigelt B; Comino-Méndez I; de Bruijn I; Tian L; Meisel JL; García-Murillas I; Fribbens C; Cutts R; Martelotto LG; Ng CKY; Lim RS; Selenica P; Piscuoglio S; Aghajanian C; Norton L; Murali R; Hyman DM; Borsu L; Arcila ME; Konner J; Reis-Filho JS; Greenberg RA; Robson ME; Turner NC
Clin Cancer Res; 2017 Nov; 23(21):6708-6720. PubMed ID: 28765325
[No Abstract] [Full Text] [Related]
13. Targeted composite value-based endpoints in platinum-sensitive recurrent ovarian cancer.
Foote JR; Secord AA; Liang MI; Ehrisman JA; Cohn DE; Jewell E; Havrilesky LJ
Gynecol Oncol; 2019 Mar; 152(3):445-451. PubMed ID: 30876487
[TBL] [Abstract][Full Text] [Related]
14. Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments.
Valenza C; Trapani D; Gandini S; Sposetti C; Boscolo Bielo L; Marra A; Giarratano T; Favero D; Cortesi L; Moscetti L; Pistelli M; Berardi R; Zambelli A; Lambertini M; Del Mastro L; Guarneri V; Vernieri C; Curigliano G
Eur J Cancer; 2023 Sep; 190():112944. PubMed ID: 37437366
[TBL] [Abstract][Full Text] [Related]
15. EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression.
Lheureux S; Oaknin A; Garg S; Bruce JP; Madariaga A; Dhani NC; Bowering V; White J; Accardi S; Tan Q; Braunstein M; Karakasis K; Cirlan I; Pedersen S; Li T; Fariñas-Madrid L; Lee YC; Liu ZA; Pugh TJ; Oza AM
Clin Cancer Res; 2020 Aug; 26(16):4206-4215. PubMed ID: 32444417
[TBL] [Abstract][Full Text] [Related]
16. Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancer.
Bookman MA; Tyczynski JE; Espirito JL; Wilson TW; Fernandes AW
Gynecol Oncol; 2017 Jul; 146(1):58-63. PubMed ID: 28454659
[TBL] [Abstract][Full Text] [Related]
17. Implications of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel monotherapy in advanced ovarian cancer.
Tan DS; Yap TA; Hutka M; Roxburgh P; Ang J; Banerjee S; Grzybowska E; Gourley C; Gore ME; Kaye SB
Eur J Cancer; 2013 Apr; 49(6):1246-53. PubMed ID: 23265709
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis.
Bartoletti M; Pelizzari G; Gerratana L; Bortot L; Lombardi D; Nicoloso M; Scalone S; Giorda G; Baldassarre G; Sorio R; Puglisi F
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32471250
[TBL] [Abstract][Full Text] [Related]
19. Emerging therapeutic modalities of PARP inhibitors in breast cancer.
Wang X; Shi Y; Huang D; Guan X
Cancer Treat Rev; 2018 Jul; 68():62-68. PubMed ID: 29870916
[TBL] [Abstract][Full Text] [Related]
20. Real-world treatment patterns of maintenance therapy in platinum-sensitive recurrent ovarian cancer.
Moss HA; Perhanidis JA; Havrilesky LJ; Secord AA
Gynecol Oncol; 2021 Oct; 163(1):50-56. PubMed ID: 34301411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]